10:05 AM EST - NetraMark Holdings Inc. : Underscored its differentiated capability to support psychedelic clinical trials in a manner distinguishable from conventional analytical approaches, potentially advancing the development of psychedelic therapies following the recent U.S. executive order aimed at accelerating innovation in this emerging field. NetraMark Holdings Inc.
shares T.AIAI are trading unchanged at $0.95.
